A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
Clinical trial NCT04740918 · TERMINATED
Trial details
- NCT number
- NCT04740918
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-07
- Primary completion
- 2024-06-19
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.